| 000 | 01248 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250513143433.0 | ||
| 264 | 0 | _c19980618 | |
| 008 | 199806s 0 0 eng d | ||
| 022 | _a0002-9149 | ||
| 024 | 7 |
_a10.1016/s0002-9149(98)00253-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDavignon, J | |
| 245 | 0 | 0 |
_aMethods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects. _h[electronic resource] |
| 260 |
_bThe American journal of cardiology _cApr 1998 |
||
| 300 |
_a17F-24F p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aClofibrate _xpharmacology |
| 650 | 0 | 4 |
_aDrug Evaluation _xmethods |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 |
_aDrugs, Investigational _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aHyperlipidemias _xdrug therapy |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xpharmacology |
| 650 | 0 | 4 | _aLegislation, Drug |
| 650 | 0 | 4 |
_aProbucol _xpharmacology |
| 773 | 0 |
_tThe American journal of cardiology _gvol. 81 _gno. 8A _gp. 17F-24F |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0002-9149(98)00253-7 _zAvailable from publisher's website |
| 999 |
_c9571593 _d9571593 |
||